玻璃体腔注射抗血管内皮生长因子药物治疗放射性视网膜病变的疗效:系统综述与Meta分析
该系统综述与Meta分析纳入7项研究(含3项随机对照试验)共922例放射性视网膜病变患者,比较玻璃体腔注射抗血管内皮生长因子(anti-VEGF)与其他疗法的疗效。结果显示,anti-VEGF治疗在改善最佳矫正视力(BCVA)和降低中央视网膜厚度(CRT)方面优于其他治疗,但结论受纳入部分非随机研究和样本量小的限制。
要点
- 与其它治疗相比,anti-VEGF治疗使BCVA平均降低-0.34 logMAR(95%CI -0.39至-0.30,I²=87.70%,P<.001)。
- anti-VEGF治疗使CRT平均降低-34.65 µm(95%CI -50.70至-18.60 µm,I²=30.40%,P<.001)。
- anti-VEGF治疗使FAZ面积平均减少-0.69 mm²(95%CI -0.91至-0.46 mm²,I²=0%,P<.001)。
核心结论
- 与其它治疗相比,玻璃体腔注射anti-VEGF在改善BCVA和降低CRT方面显示出更优疗效,提示anti-VEGF可能改善放射性视网膜病变的结局。
- 结论受纳入部分非随机研究数据和样本量小的限制。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Web of Science、Scopus和Cochrane Library自建库至2023年12月15日的文献。
- 纳入报告玻璃体腔anti-VEGF治疗放射性视网膜病变患者BCVA的随机对照试验和非随机研究。
- 共纳入7项研究(包括3项随机对照试验),涵盖922例放射性视网膜病变患者。
- 由2名独立评价者进行研究选择和数据提取,采用Cochrane RoB 2.0和ROBINS-I工具评估偏倚风险,使用Q、H和I²统计量量化异质性。
主要发现
- 与其它治疗方式相比,anti-VEGF治疗使BCVA平均降低-0.34 logMAR(95%CI -0.39至-0.30 logMAR;I²=87.70%;P<.001)。
- 与其它治疗方式相比,anti-VEGF治疗使CRT平均降低-34.65 µm(95%CI -50.70至-18.60 µm;I²=30.40%;P<.001)。
- 与其它治疗方式相比,anti-VEGF治疗使FAZ面积平均减少-0.69 mm²(95%CI -0.91至-0.46 mm²;I²=0%;P<.001)。
- anti-VEGF与其他治疗干预之间,浅层毛细血管丛的毛细血管密度呈现积极趋势。
局限性
- 结论受纳入部分非随机研究数据的限制。
- 结论受样本量小的限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to appraise the therapeutic effectiveness of intravitreal injections anti-vascular endothelial growth factor (anti-VEGF) vs alternative therapies in managing radiation retinopathy (RR). DESIGN: Systematic review and meta-analysis. METHODS: We obtained comprehensive data retrieval using PubMed, Embase, Web of Science, Scopus, and the Cochrane Library from their inception until December 15, 2023. This review included randomized controlled trials (RCTs) and nonrandomized studies (NRSs) reporting on best-corrected visual acuity (BCVA) among RR patients treated with intravitreal anti-VEGF. Study selection and data extraction were meticulously performed by 2 independent reviewers. The Cochrane Risk of Bias Tool 2.0 (RoB 2.0) and Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) scales were utilized for bias risk assessment. Quantification of heterogeneity was executed using Q, H, and I2 statistics. The primary endpoint was the BCVA at the final observation point of each study. Secondary endpoints included central retinal thickness (CRT), foveal avascular zone (FAZ) area, and capillary density (CD) at the level of superficial capillary plexus. Subgroup analyses were undertaken to explore potential heterogeneity sources possibly due to treatment duration and study design. Sensitivity analyses were conducted to ascertain result stability. RESULTS: This analysis incorporated 7 studies (including 3 RCTs) encompassing 922 patients afflicted with RR. Relative to other treatment modalities, intravitreal anti-VEGF therapy was associated with a statistically significant mean decrease in BCVA of -0.34 logMAR (95% CI, -0.39 to -0.30 logMAR; I2 = 87.70%; P < .001), and a substantial reduction in CRT of -34.65 µm (95% CI, -50.70 to -18.60 µm; I2 = 30.40%; P < .001). Additionally, a reduction in the FAZ area by -0.69 mm² (95% CI, -0.91 to -0.46 mm², I2 = 0%; P < .001) was observed. A positive tendency was noted in CD at the superficial capillary plexus between anti-VEGF and other therapeutic interventions. CONCLUSIONS: Intravitreal anti-VEGF injections, in comparison to other treatments, demonstrate superior efficacy in enhancing BCVA and reducing CRT, thereby underscoring the potential of anti-VEGF in ameliorating radiation retinopathy outcomes. However, the conclusions are constrained by the incorporation of data from some NRSs and the small sample sizes.
引用
- Zhuang J, Yang Y, Liao Y, et al. Efficacy of Intravitreal Injections Anti-Vascular Endothelial Growth Factor Treatment for Radiation Retinopathy: A Systematic Review and Meta-analysis. Am J Ophthalmol. 2024. PMID: 38458409. doi:10.1016/j.ajo.2024.02.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。